Teva Pharmaceutical Industries Limited (NYSE:TEVA) Downgraded by Vetr Inc. to “Hold”

Vetr downgraded shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) from a buy rating to a hold rating in a research note released on Wednesday, July 12th. Vetr currently has $31.74 target price on the stock.

Several other analysts have also recently issued reports on TEVA. Jefferies Group LLC restated a hold rating and set a $33.00 target price on shares of Teva Pharmaceutical Industries Limited in a research report on Friday, June 23rd. BTIG Research restated a neutral rating on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, April 6th. Wells Fargo & Company restated a hold rating on shares of Teva Pharmaceutical Industries Limited in a research report on Tuesday, June 27th. BidaskClub raised shares of Teva Pharmaceutical Industries Limited from a strong sell rating to a sell rating in a research report on Tuesday, June 13th. Finally, Cantor Fitzgerald started coverage on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, June 15th. They issued a neutral rating and a $31.00 price objective on the stock. Three equities research analysts have rated the stock with a sell rating, nineteen have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of Hold and an average price target of $37.69.

Shares of Teva Pharmaceutical Industries Limited (TEVA) traded up 0.64% on Wednesday, hitting $17.30. The stock had a trading volume of 25,100,576 shares. The company’s market capitalization is $17.58 billion. Teva Pharmaceutical Industries Limited has a 52 week low of $16.81 and a 52 week high of $55.39. The company has a 50-day moving average of $29.64 and a 200 day moving average of $31.56.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by $0.07. The business had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The firm’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.25 earnings per share. On average, equities research analysts predict that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.com-unik.info/2017/08/12/teva-pharmaceutical-industries-limited-nyseteva-lowered-to-hold-at-vetr-inc-updated-updated-updated.html.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 14th. Investors of record on Tuesday, August 29th will be issued a dividend of $0.085 per share. The ex-dividend date is Friday, August 25th. This represents a $0.34 annualized dividend and a dividend yield of 1.97%. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is presently -18.95%.

Hedge funds and other institutional investors have recently modified their holdings of the company. Cribstone Capital Management LLC boosted its position in shares of Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock valued at $101,000 after buying an additional 100 shares during the period. Bronfman E.L. Rothschild L.P. boosted its position in shares of Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock valued at $116,000 after buying an additional 261 shares during the period. Kistler Tiffany Companies LLC boosted its position in shares of Teva Pharmaceutical Industries Limited by 74.7% in the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock valued at $122,000 after buying an additional 1,571 shares during the period. FNY Managed Accounts LLC acquired a new position in shares of Teva Pharmaceutical Industries Limited during the first quarter valued at about $123,000. Finally, Sterling Investment Advisors Ltd. boosted its position in shares of Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after buying an additional 100 shares during the period. 56.27% of the stock is owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

What are top analysts saying about Teva Pharmaceutical Industries Limited? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teva Pharmaceutical Industries Limited and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit